Statera Biopharma gets go-ahead for next phase of Crohn’s therapy trial
FORT COLLINS — Statera Biopharma Inc. (Nasdaq: STAB) has received approval from the Central Institutional Review Board to move forward with the third phase of its clinical trial for STAT-201, its candidate for the treatment of pediatric Crohn’s Disease.
“IRB approval to proceed with our Phase 3 trial is an important step for the development of STAT-201, one that potentially may lead to better treatment for pediatric patients whose lives are significantly impacted by the physical and emotional burdens of CD,” Statera CEO Michael Handley said in a prepared statement. “STAT-201, our most advanced drug candidate, is an immune modulator that can provide for the restoration of mucosal healing and intestinal barrier function as an adjunct to standard of care in CD.”
Patient enrollment in the company’s upcoming clinical trial is expected to start in the second quarter of this year.